Navigation Links
WellPoint Announces Acquisition of DeCare Dental
Date:4/29/2008

linkage between poor oral health and serious medical conditions such as cardiovascular disease, diabetes, and increased risk of pre-term low birth weight babies," said Dennis Casey, President and CEO of WellPoint's UniCare and Specialty businesses. "An integrated health benefits plan that includes medical and dental coverage provides consumers with important preventative services that focus on overall well-being and good health."

DeCare currently serves 10 dental plans, primarily as a third party administrator. DeCare also operates DeCare Systems Ireland (DSI), which offers custom enterprise software solutions, e-business applications and application performance tuning and is also the first American company to offer dental benefits in Ireland as Vhi DeCare Dental.

Upon the completion of the acquisition, WellPoint's dental company will provide and administer dental benefits to 9 million members and have one of the nation's largest dental PPO networks.

About WellPoint, Inc.

WellPoint's mission is to improve the lives of the people it serves and the health of its communities. WellPoint, Inc. is the largest health benefits company in terms of commercial membership in the United States. Through its nationwide networks, the company delivers a number of leading health benefit solutions through a broad portfolio of integrated health care plans and related services, along with a wide range of specialty products such as life and disability insurance benefits, pharmacy benefit management, dental, vision, behavioral health benefit services, as well as long term care insurance and flexible spending accounts. Headquartered in Indianapolis, Indiana, WellPoint is an independent licensee of the Blue Cross and Blue Shield Association and serves its members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area),
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. WellPoint Foundation Supports National Campaign Focused on Depression Among Men
2. WellPoint Reports First Quarter 2008 Results
3. Shareholder Class Action Filed Against WellPoint, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
4. WellPoint Appoints Kevin R. Hayden as President of State Sponsored Business
5. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of WellPoint, Inc. Who Invested in the WellPoint Retirement Savings Plan
6. WellPoint to Hold Conference Call and Webcast to Discuss First Quarter Results On April 23, 2008
7. WellPoints Health Plans to Cover Newly Approved Cancer Treatment
8. WellPoint Announces Appearances at Upcoming Conferences
9. WellPoint Revises 2008 Earnings Per Share Guidance
10. WellPoint Announces Appearance at Upcoming Conference
11. WellPoint Reports Fourth Quarter and Full Year 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...ufacturers who use medical load cells at the heart...by bringing in technology partner Flintec early in...ive medical manufacturers are calling in Flintec l...jects, ensuring that progress will not be constrai...tdated technology. , (PRW...
(Date:11/26/2009)...PRNewswire/ -- The diabetes population in the Unit...s and annual medical spending on the disease is pr...today, according to a study published in the Decem...ing Diabetes ® Program (NCDP), a program of N...rom the University of Chicago. ,, According to ...
(Date:11/26/2009)...lead to strains or worse , , THURSDAY, N...ong with stuffing your turkey full to bursting, bu...r suitcase as you pack for holiday trips. , Mor...hospital emergency rooms, doctors, offices, clinic... injuries, such as muscle strains, pulls and tears...
(Date:11/26/2009)...of the Live Life Again Center, a practice offering...ing number of physicians who are taking advantage...h individuals who are interested in surgical weigh...is utilizing Facebook to share before-and-after ph...ommunity. , Dallas, TX (V...
(Date:11/26/2009)...nis, P.A. is offering free nationwide confidential...ontrol pills who have suffered a Deep Vein Thrombo...k or other related cardiac issues or had their Gal...0-856-6405 or go to the firm’s website at h...e evaluation form. , (PRW...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3
... blood pressure under 70 mm Hg coupled with an ele...isk of heart attack and stroke than indicated by t... to a UC Irvine study. , Dr. Stanley Franklin and...ta from 9,657 participants in the Framingham Heart...
...Y 08 and Record Quarterly Operating Income , , HO... today announced results for the quarter ended Jan...ults for the third quarter of fiscal 2009 compared...nslations reducing third quarter sales by an estim...
... new study,s finding, , , WEDNESDAY, Feb. ...cked heart arteries, bypass surgery produced bette...f a stent, and thus "remains the standard of care"... who wrote an accompanying editorial. , The benefi...
...he Westaim Corporation announced today that for th...loss of $10.2 million, or 11 cents per share, on r... $58.0 million, or 62 cents per share, on revenues...share, compared to a net loss of $26.8 million, or...
...lent than full-blown stroke in people under 65, MR...thDay News) -- "Silent strokes" rarely produce sym...st five times more common than full-blown strokes ...f Medicine as a part of the ongoing Framingham Hea...
... Journal of the American Medical,Association ( J... Bioinformatics at the National Institute of Stati...h Columbia, highlight the statistical limitations ...tudy, published in JAMA (September 16, 2008) by ...
Other Medicine News:Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 2Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 3Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 4Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 5Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 6Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 7Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 8Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 9Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 10Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 11Health News:Is Bypass Truly Better than Stenting? 2Health News:Is Bypass Truly Better than Stenting? 3Health News:Westaim announces 2008 year-end results 2Health News:Westaim announces 2008 year-end results 3Health News:Westaim announces 2008 year-end results 4Health News:Westaim announces 2008 year-end results 5Health News:Westaim announces 2008 year-end results 6Health News:Westaim announces 2008 year-end results 7Health News:Westaim announces 2008 year-end results 8Health News:Westaim announces 2008 year-end results 9Health News:Westaim announces 2008 year-end results 10Health News:Westaim announces 2008 year-end results 11Health News:Westaim announces 2008 year-end results 12Health News:Silent Strokes More Common in Younger People Than Thought 2Health News:Silent Strokes More Common in Younger People Than Thought 3
(Date:11/25/2009)... Nov. 25 Reportlinker.com announce...n its catalogue: ,, Mammography Equipment - A...ortlinker.com/p0164330/Mammography-Equipment---A-G...nce of breast cancer in industrialized as well as ...ng growth in the mammography market. Globally, esc...
(Date:11/25/2009)..., N.C., Nov. 25 Cempra Pharmaceuti...es, president and chief executive officer, will pr... Conference at 8:50 a.m. EST, December 1, 2009, at...Fernandes will provide an overview of the company,... treatment of drug-resistant pathogens including M...
(Date:11/25/2009)...alif., Nov. 25 ChemoCentryx, Inc... from the Company,s PROTECT-1 (the Prospective Ran... Trial) of Traficet-EN(TM) (CCX282-B) in patients ...ed clinical efficacy with a favorable safety and t...nce of clinical efficacy in the reduction of disea...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Long Term Care Consumer Voices Strengthened 58768 1Long Term Care Consumer Voices Strengthened 58768 2Yongye International Announces 2010 2012 Strategic Plan 14335 1Yongye International Announces 2010 2012 Strategic Plan 14335 2Yongye International Announces 2010 2012 Strategic Plan 14335 3Yongye International Announces 2010 2012 Strategic Plan 14335 4Yongye International Announces 2010 2012 Strategic Plan 14335 5Face Masks Offer Protection Against Spreading H1N1 5187 1Face Masks Offer Protection Against Spreading H1N1 5187 2
... 3 Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) an... milestones,achieved in 2008 and preview objective...Briefing to be held in New York City today. , Da...poration,s Research,Biotech Business Unit will dis...o companies, collaboration to commercialize zinc f...
...f., Dec. 3 Isis Pharmaceuticals,Inc. (Nasdaq: I...ls, Inc.,provided positive survival results from a...ombination with docetaxel and prednisone ("the OGX...one ("the control arm") for first-line,treatment o...The current 10.6,month median overall survival adv...
Other Medicine Technology:Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4
MIS Distal Femoral Alignment/Saw Guide and Intramedullary Rod
Ascent Anterior Referencing Femoral Instrument Case
Ascent Knee System Case # 2
Lineage Acetabular Cup System (Ceramic)
Medicine Products: